蜜环菌多糖对损伤性胰岛细胞分泌功能的影响

培养大鼠胰岛素瘤细胞(INS-1),以四氧嘧啶(AXN)损伤细胞,培养液中加入不同浓度的多糖AMP-1,检测不同浓度AMP-1对INS-1细胞葡萄糖刺激的胰岛素和C肽分泌量的影响,同时检测细胞存活率。结果表明,一定浓度范围AMP-1对AXN损伤的INS-1细胞分泌胰岛素和C肽均具有一定的促进作用,尤其是在葡萄糖刺激浓度为16.7mmol·L-1时,效果显著;AMP-1可减少AXN对INS-1细胞的损伤,使INS-1细胞存活率增加。     

Stimulation of insulin and glucagon synthesis in rat Langerhans islets by malathion in vitro: Evidence for mitochondrial interaction and involvement of subcellular non-cholinergic mechanisms

We examined the effects of malathion, an organophosphorus (OP) insecticide, on glucagon, C-peptide, and insulin content or secretion from isolated rat Langerhans islets in vitro. Islets were isolated from the pancreas of rats by standard collagenase digestion, separation by centrifugation, and hand-picking technique. Then islets were cultured in medium and supplemented with various concentrations of malathion (25, 125, and 625 μg/ml) for 1, 3, and 5 h. In vitro exposure to malathion increased insulin and C-peptide contents at doses of 25, 125, and 625 μg/ml following 5 h incubation as compared to control. All doses of malathion increased glucagon content after 3 and 5 h as compared to control. Increase of the glucagon content at all doses in the fifth hour was higher than that of third hour. Malathion also decreased 2.8 and 16.7 mM glucose-stimulated insulin secretion at all doses after 30 min as compared to control.It is concluded that malathion reduce insulin exocytose in a short time (first hour) but after a long time (e.g., 5 h), the content of insulin is increased by compensating mechanisms such as resynthesize of insulin or aggregation of insulin. The present in vitro study for the first time proposes the involvement of subcellular non-cholinergic mechanisms in malathion-induced changes in Langerhans islets insulin and glucagon.     

Efficacy and safety of allogenic canine adipose tissue-derived mesenchymal stem cell therapy for insulin-dependent diabetes mellitus in four dogs: A pilot study

Mesenchymal stem cells (MSCs) possess regenerative and immunomodulatory properties and can control the immune dysregulation that leads to β-cell destruction. Stem-cell transplantation could thus manage insulin-dependent diabetes mellitus (IDDM) in dogs. In this pilot study, we aimed to assess canine adipose tissue-derived MSCs (cAT-MSCs) transplantation as a treatment for canine diabetes mellitus. This study included four dogs with over a year of insulin treatment for IDDM, following diagnosis at the Veterinary Medicine Teaching Hospital of Seoul National University. Allogenic cAT-MSCs were infused intravenously three or five times monthly to dogs with IDDM. Blood and urine samples were obtained monthly. General clinical symptoms, including changes in body weight, vitality, appetite, and water intake were assessed. Three of the four owners observed improvement of vitality after stem cell treatment. Two of the four dogs showed improvement in appetite and body weight, polyuria, and polydipsia. C-peptide has increased by about 5–15% in three of the cases, and fructosamine and HbA1c levels have improved in two of the cases. Hyperlipidemia was resolved in two of the dogs, and there was no concurrent bacterial cystitis in any of the dogs. C-peptide secretion and lipid metabolism are associated with diabetic complications. Improvement in these parameters following the treatment suggests that cAT-MSC transplantation in dogs with IDDM might help to improve their insulin secretory capacity and prevent diabetic complications.